Abstracts tagged "Disease Activity"

Abstract Number: 0584 • ACR Convergence 2024
Effectiveness of Tofacitinib Monotherapy versus Combination Therapy in Patients with Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondylarthritis Registry
Alexis Ogdie¹, Nicole Middaugh², Taylor Blachley², Tran Bourgeois³, You-Li Ling⁴, Rajiv Mundayat⁴, Lara Fallon⁵, Karim Masri⁶ and Philip Mease⁷, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Real-world (RW) data on the effectiveness of tofacitinib in patients (pts) with PsA are limited. This study summarized disease activity and pt‑reported outcome measures…
Abstract Number: 0802 • ACR Convergence 2024
Disease Activity Is Strongly Associated with RA-related Lung Disease and Interstitial Lung Disease in Early RA: Results from a Multicenter, Prospective Cohort Study
Gregory McDermott¹, Ritu Gill², Suzanne Byrne³, Staci Gagne³, Xiaosong Wang⁴, Misti Paudel⁵, Emily Kowalski³, Grace Qian⁴, Katarina Bade³, Kevin Mueller³, Alene Saavedra³, Kathleen Vanni³, Caleb Bolden⁶, Tina Mahajan⁷, Erica Mulcaire-Jones⁸, Neda Kortam⁸, Pierre-Antoine Juge⁹, Tracy J Doyle¹⁰, Zachary Wallace¹¹, Marcy Bolster⁶, Kevin Deane¹², Dinesh Khanna⁸, Bryant England⁷ and Jeffrey Sparks¹³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁶Massachusetts General Hospital, Boston, MA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸University of Michigan, Ann Arbor, MI, ⁹Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ¹⁰Brigham and Women's Hospital, West Roxbury, MA, ¹¹Massachusetts General Hospital, Newton, MA, ¹²University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: RA is associated with several forms of lung disease including interstitial lung disease (ILD), bronchiectasis, and emphysema. Risk factors for the development and progression…
Abstract Number: 1262 • ACR Convergence 2024
The Relationship Between Child Opportunity Index and Burden of Pediatric Systemic Lupus Erythematosus
Ayah Eltoum¹, Livie Timmerman², Melissa Mannion¹ and Emily Smitherman¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Gardendale, AL
Background/Purpose: Outcomes for systemic lupus erythematosus are known to be associated with sociodemographic indicators. The Child Opportunity Index (COI) is a well-validated measure of neighborhood…
Abstract Number: 1362 • ACR Convergence 2024
Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
Peter C. Taylor¹, Aditi Kadakia², Jack Milligan³, Sander Strengholt², Oliver Howell³, Pankaj Patel², Sophie Barlow³ and Roberto Caporali⁴, ¹University of Oxford, Oxford, United Kingdom, ²AbbVie Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy
Background/Purpose: Network meta-analyses of phase 3 clinical trial data involving JAK inhibitor (JAKi)-treated patients with RA and an inadequate response to conventional synthetic DMARDs showed…
Abstract Number: 1483 • ACR Convergence 2024
Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors
SAUMYA TRIPATHY¹, DEBASISH PANDIT², Sarit Pattanaik³, Liza Rajasekhar⁴, VINEETA SHOBHA⁵, Chengappa Kavadichanda⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Ranjan Gupta⁹, Manish Rathi¹⁰, AVINASH JAIN¹¹, MANOJ PARIDA¹², Bidyut Das¹³ and Amita Aggarwal¹⁴, ¹SCB Medical College, Cuttack, Odisha, India, Cuttack, Orissa, India, ²SJM MCH, Puri, Puri, Orissa, India, ³SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, Orissa, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ⁵ST JOHN'S MEDICAL COLLEGE, BENGALURU, Karnataka, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷Christian Medical College, Vellore, Tamil Nadu, India, ⁸Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁹All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹⁰Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹¹SMS MCH, JAIPUR, JAIPUR, Rajasthan, India, ¹²SCB MEDICAL COLLEGE, CUTTACK, Cuttack, Orissa, India, ¹³SCB Medical College, Cuttack, Orissa, India, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Infections in SLE are a major cause of morbidity and mortality. The susceptibility to infections in SLE is multifactorial. Immune dysregulation, immunosuppressive drug use and…
Abstract Number: 1777 • ACR Convergence 2024
Broad Proteomic Analysis Reveals Top Differential Protein Modules and Functional Annotations with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
Amy Kaneshiro¹, Adeline Chin¹, Lisa Rider², Frederick Miller³, Foo Cheung⁴, Megan Darrell¹, Angelique Biancotto⁴, Ujana Zajmi¹ and Hanna Kim⁵, ¹NIH/NIAMS, Bethesda, MD, ²NIEHS, NIH, Garrett Park, MD, ³NIH, NIEHS, Chapel Hill, NC, ⁴NIH/NIAID, Bethesda, MD, ⁵National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: JDM is a heterogenous systemic autoimmune disease with muscle and skin pathology, which can be clinically subgrouped by MSAs (ex: anti-TIF1, anti-MDA5 autoantibodies (Ab)).…
Abstract Number: 2217 • ACR Convergence 2024
A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity
Gilad Halpert¹, Eri Govrin², Boris Gilburd³, Shlomo Segev³, Omer Gendelman⁴, Abdulla Watad⁵, Yehuda Shoenfeld⁶, David Meiri⁷ and Howard Amital⁸, ¹CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, ²Sheba Medical Center, Sdot Micha, Israel, ³Sheba Medical Center, Ramat-Gan, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Tel Hashomer Medical Center, Ramat Gan, Israel, ⁶sheba medical center , Israel, Ramat Gan, Israel, ⁷Technion-Israel Institute of Technology, Haifa, Israel, ⁸Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel
Background/Purpose: Accumulating evidence suggests that medical cannabis therapy might have beneficial therapeutic effects in the fibromyalgia syndrome (FMS) and in difficult-to-treat rheumatoid arthritis (RA) patients.…
Abstract Number: 2377 • ACR Convergence 2024
Impact of Neighborhood Area Deprivation Index on Outcomes in Lupus Patients in Bronx, NY
Anitha Ramu¹, Justina Shafik², Maedeh Ashrafi³, Juliann Allen², Kiera Brennan¹ and Noa Schwartz⁴, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Jacobi Medical Center, Bronx, NY, ⁴Albert Einstein College of Medicine, New York, NY
Background/Purpose: Studies have demonstrated that socioeconomic status (SES) significantly influences outcomes of patients with SLE.1 Traditionally, tools such as income, education, occupation, and housing have…
Abstract Number: 0043 • ACR Convergence 2024
Inflammatory and Angiogenic Serum Profile of Refractory Rheumatoid Arthritis
Manon Lesturgie-Talarek¹, Virginie Gonzalez², ALICE COMBIER³, Marion THOMAS⁴, Margaux Boisson⁵, Sandrine Carves³, Sarah Wanono³, Lucie Poiroux³, Anne Cauvet¹, Sophie Hecquet⁶, Yannick Allanore⁷ and Jérôme Avouac⁸, ¹Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ²Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, Ile-de-France, France, ³Hôpital Cochin - Université Paris Cité, Paris, France, ⁴APHP, Paris, France, ⁵Hôpital Cochin - Université Paris Cité, Paris, ⁶Cochin Hospital, Paris, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Despite the emergence of new therapies, a considerable proportion of individuals with rheumatoid arthritis (RA) still endure symptoms, giving rise to the concept of…
Abstract Number: 0500 • ACR Convergence 2024
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years
Kevin Winthrop¹, Daniel Aletaha², Roberto Caporali³, Yoshiya Tanaka⁴, Tsutomu Takeuchi⁵, Vikas Modgill⁶, Edmund V. Ekoka Omoruyi⁷, Dick de Vries⁸, Katrien Van Beneden⁹, Jacques-Eric Gottenberg¹⁰ and Gerd Burmester¹¹, ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Clinical Development, Galapagos BV, Leiden, Netherlands, ⁹Medical Affairs, Galapagos NV, Mechelen, Belgium, ¹⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The oral Janus kinase 1-preferential inhibitor filgotinib (FIL) is approved at doses of 100 mg (FIL100) and 200 mg (FIL200) for the treatment of…
Abstract Number: 0599 • ACR Convergence 2024
Sex- related Differences in Efficacy of Biologics in Axial Spondyloarthritis: A Systematic Review and Meta-analysis
Haseeb Chaudhary¹, Omer Pamuk², Sarah Abi Doumeth³, Ansaam Daoud⁴, Muhammad Shamim⁵ and Marina Magrey⁶, ¹Case Western Reserve University, Westlake, OH, ²University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ³Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland Heights, OH, ⁴Case Western Reserve University/University Hospitals, Akron, OH, ⁵University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ⁶Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: There is limited information about sex-related differences in efficacy of biologics in axial spondyloarthritis (axSpA). We hypothesized that females with axSpA are less likely…
Abstract Number: 0818 • ACR Convergence 2024
Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Lykke Oernbjerg¹, Brigitte Michelsen², Tore K. Kvien³, Simon Horskjær Rasmussen⁴, Jakub Závada⁵, Kristýna Bubová⁶, Bente Glintborg⁷, Anne Gitte Loft⁸, Ana Maria Rodrigues⁹, Maria Jose Santos¹⁰, Adrian Ciurea¹¹, Michael Nissen¹², Laura Kuusalo¹³, Jarno Rutanen¹⁴, Ziga Rotar¹⁵, Katja Perdan-Pikmajer¹⁵, Bjorn Gudbjornsson¹⁶, Olafur Palsson¹⁷, Daniela DiGuiseppe¹⁸, Mikkel Ostergaard¹⁹ and Merete Hetland²⁰, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴Rigshospitalet Glostrup, Glostrup, Denmark, ⁵Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁶Institute of Rheumatology and Charles University, Prague, Czech Republic, ⁷DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ⁸Aarhus University Hospital and Aarhus University, Horsens, Denmark, ⁹Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, ¹⁰Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ¹¹University Hospital Zurich, Zürich, Switzerland, ¹²Geneva University Hospital, Geneva, Switzerland, ¹³University of Turku and Turku University Hospital, Turku, Finland, ¹⁴Tampere University Hospital, Tampere, Finland, ¹⁵University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁶Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁷University of Iceland and Skåne University Hospital, Reykjavik, Iceland, ¹⁸Karolinska Institutet, Stockholm, ¹⁹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ²⁰Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: While the Axial Spondyloarthritis Disease Activity Score based on C-reactive protein (ASDAS) is recommended for assessment of disease activity in patients with axial spondyloarthritis…
Abstract Number: 1263 • ACR Convergence 2024
Assessing Lupus Low Disease Activity State in the Pediatric Rheumatology Clinic: Baseline Data Collection from a Pediatric Lupus Collaborative
Emily Smitherman¹, Julia Harris², Aimee Hersh³, Jennifer Huggins⁴, Ashley Lytch⁵, Hanh Ho⁶, Ashley Meyer⁷, Megan Quinlan-Waters⁴, Livie Timmerman⁸ and Jon Burnham⁹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Children's Mercy Kansas City, Overland Park, KS, ³University of Utah, Salt Lake City, UT, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Children's Mercy Hospital, Kansas City, MO, ⁶Children's Mercy Kansas City, Kansas City, ⁷Children's Hospital of Philadelphia, Philadelphia, ⁸University of Alabama at Birmingham, Gardendale, AL, ⁹Children's Hospital of Philadelphia, Bryn Mawr, PA
Background/Purpose: Achievement of a lupus low disease activity state (LLDAS) has been associated with less organ damage, fewer disease flares, and improved health-related quality of…
Abstract Number: 1364 • ACR Convergence 2024
Machine Learning-Driven Models for Disease Activity Prediction and Therapeutic Response Evaluation in Rheumatoid Arthritis Patients: An Analysis of Data from the Multicentre, Prospective, Egyptian Collage of Rheumatology (ECR) Study Group
Nevin Hammam¹, Tarek Nahool², A. M. Yasser³, Eman F Mohamed⁴, Samar Tharwat⁵, Doaa Mosad Mosa⁶, Maha Nassr⁷, Faten Ismail⁸, Rawhya R El Shereef⁸, Nora Y. Elsaid⁹, Osman Hammam¹⁰, Suzan S. Al‑Adle⁹ and Tamer A Gheita¹¹, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Boston, MA, ²University of the People, Pasadena, CA, USA, Qena, Egypt, ³Physics Department, Faculty of Science, South Valley University, Qena, Egypt; Alchemy Research, Alchemy Global Solutions, Abu Dhabi, UAE, Abu Dhabi, United Arab Emirates, ⁴Internal Medicine Department, Rheumatology Unit, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt, ⁵Rheumatology Unit, Internal Medicine, Mansoura University, Dakahlia, ⁶Rheumatology & Rehabilitation Department, Mansoura University Hospitals, Mansoura University Faculty of Medicine, Egypt, Dakahlia, Egypt, ⁷Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt, Fayoum, Egypt, ⁸Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Department of Rheumatology and Rehabilitation, Faculty of Medicine, New Valley University, New Valley, Assiut, Egypt, ¹¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Rheumatoid arthritis (RA) often exhibits fluctuating and challenging-to-assess clinical courses that lead to irreversible joint destruction. However, a "Treat-to-Target" strategy is recommended aiming to…
Abstract Number: 1499 • ACR Convergence 2024
Outcome of Newly Onset SLE with Neuropsychiatric Symptoms and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Shuzo Sato, Fumitaka Seike, Yuya Sumichika, Kenji Saito, Shuhei Yoshida, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka and Tomoyuki Asano, Fukushima Medical University, Fukushima, Fukushima, Japan
Background/Purpose: Although neuropsychiatric (NP) symptoms may occur in patients with SLE even in initial onset, studies regarding the distinct clinical features of SLE patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].